

Collaborative Working Project Summary

Project title	Weight Management & Complex Obesity Service (WMCOS) Single Point of Access (Risk Stratification & Referral Management) across Suffolk and North East Essex (SNEE)
Organisations involved	Suffolk and North East Essex ICB (SNEE ICB)
Overview / Rationale for the project	This collaborative working project between Novo Nordisk UK and NHS SNEE ICB aims to embed an AI-enabled digital triage system for the WMCOS. The project focuses on providing equitable access to care through a single referral system that brings local authority and NHS-commissioned services into a single workflow.
Aims and objectives of the project	<p>The project aims to establish a digitally enabled single point of access for weight management and complex obesity referrals across SNEE ICB.</p> <p>Key Objectives:</p> <ul style="list-style-type: none"> • Improve overall efficiency in referral processing, risk stratification and routing for WMCOS • Transform the tiered care structure to a fully integrated model • Develop a patient-centred, Cardiovascular Renal Metabolic (CVRM) obesity and weight management assessment • Ensure appropriate and timely management of obesity and weight related co-morbidities • Reduce waiting times for specialist support • Improve Patient Reported Evaluation Measures (PREMs) • Expand access to weight management treatments with appropriate care and support
Time period (from/to)	The project aims to commence in November 2025 and will run for 12 months.
Expected benefits of the project	<p>Benefit to patients:</p> <p>Patient centric evidence-based assessment that will improve management of obesity and weight related co-morbidities.</p> <p>Reduction in waiting time for specialist support and an optimised patient journey with appropriate wrap around care and support.</p>

	<p>Benefit to NHS/other Organisations:</p> <p>The project will demonstrate how AI-enabled triage can transform integrated obesity care across SNEE ICB.</p> <p>This will provide the NHS with a framework for national reference and highlight areas for further integration of CVRM pathways via prioritisation of patients with relevant comorbidities.</p> <p>Benefit to Novo Nordisk:</p> <p>Novo Nordisk UK is pleased to collaborate with NHS SNEE to gain a better understanding of triaging, onboarding and treatment of high-risk patients living with obesity across a whole system. There is an opportunity to share learnings of this novel AI project with other NHS organisations and partners.</p> <p>As Novo Nordisk and other manufacturers supply medicines indicated for weight management and obesity, the project may lead to increased use of these medicines in line with local and national guidelines.</p>
Resource contribution from each organisation involved and roles and responsibilities of each party.	<p>Total Project Value: £252,188</p> <p>Novo Nordisk UK Contribution: £116,600 (£72,000 funding & £44,600 resources)</p> <p>SNEE ICB Contribution: £135,588 (£96,214 & £39,374 resources)</p> <p>Novo Nordisk is the sole pharmaceutical company involved in this collaborative working project. Novo Nordisk will provide project management, stakeholder engagement, governance, obesity-management expertise, service redesign, and medical communications, without access to patient data or influence on clinical decision-making and is responsible for annual transfer of value disclosures.</p> <p>SNEE ICB will provide project management and governance, ensure alignment with NHS policy, and commission providers and partners to deliver the project and evaluation. A joint steering committee of SNEE ICB and Novo Nordisk personnel will oversee project decisions and ensure completion of milestones set out in the collaborative working agreement.</p>